No Data
Transcode Therapeutics Inc Trading Halted, Volatility Trading Pause
Top Midday Gainers
HC Wainwright & Co. Reiterates Buy on TransCode Therapeutics, Maintains $20 Price Target
H.C. Wainwright Maintains Transcode Therapeutics(RNAZ.US) With Buy Rating, Maintains Target Price $20
TransCode Therapeutics Shares Are Trading Higher After the Company Announced the Completion of Its Cohort 3 Initial Dosing for Its Phase 1 Trial of TTX-MC138.
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing With Lead Candidate in Phase 1 Clinical Trial
